As 2025 comes to a close, we’re reflecting on a year of important scientific advances and encouraging clinical insights reported on Lp(a) Forum. From deepening our understanding of Lp(a) biology to highlighting important new clinical data, here are some key developments that shaped the field this year:
Lp(a) drives atherosclerosis events
Elevated Lp(a) levels were associated with continuously increased risk of recurrent atherosclerotic cardiovascular (CV) disease events, irrespective of sex and ethnicity, highlighting the unmet need for Lp(a) lowering therapy in diverse populations.
- Lp(a) drives recurrent ASCVD events
- Elevated Lp(a) and coronary artery disease severity
- High Lp(a) linked to CHD events in absence of traditional risk factors
Lp(a) Testing Policy & Advocacy
The Brussels International Declaration called for broader Lp(a) testing and management as part of CV health strategies, and further guidance highlighted the importance of Lp(a) testing and levels at which Lp(a) should be considered a CV risk factor. There was also evidence of the cost effectiveness of Lp(a) testing in high income countries.
- Brussels Declaration calls for Lp(a) testing in CV health plans
- ESC/EAS add Lp(a) recommendation in new dyslipidaemia focused update
- UK lipid guidance recommends Lp(a) measurement in enhanced lipid profiling
- Lp(a) testing is cost effective in high income countries
Therapeutic Insights
Further Phase 2 data supported the efficacy and safety of Lp(a) targeting agents, and recruitment to major Phase 3 cardiovascular outcomes trials of Lp(a) lowering therapies gathered pace.
- Update on Phase 2/3 investigations of lepodisiran and muvalaplin
- Update on the olpasiran clinical development programme
- Lp(a)HORIZON cardiovascular outcome trial
- Clinical trials targeting Lp(a) – What’s new?
- OCEAN(a)-DOSE trial shows olpasiran reduces OxPL-apoB
- ALPACA trial shows sustained Lp(a) reductions with lepodisiran
Making clinical trials more inclusive
Breaking down the barriers for inclusion of typically underrepresented populations in cardiovascular clinical trials can pay off, as shown by the rapid, successful recruitment to the Lp(a)FRONTIERS EXPANSION trial.
- Addressing barriers to clinical trial recruitment pays off
- One size fits all? Does the same Lp(a) concentration confer the same cardiovascular risk across ethnicities?
Overall, 2025 was a year of validation, clinical insights, and forward-looking evidence — moving us closer to better understanding, management, and ultimately treatment of elevated Lp(a) across diverse populations.
